FDA approves new treatment for polycythemia vera

The FDA has approved rusfertide (Mimrylo), a novel medication, for adults with polycythemia vera to manage erythrocytosis. This approval is significant as it provides a new option for patients whose high red blood cell levels are not adequately controlled by current therapies, addressing a previously unmet medical need.